Table 4.

Odds Ratios for 30-day Postoperative Complications for Patients with Adenocarcinoma of the Pancreas after Pancreaticoduodenectomy

	Crude		Adjusted*
	OR (95% CI)	p-value	OR (95% CI)	p-value
Organ space SSI
Neoadjuvant Therapy	0.70 (0.54, 0.91)	0.007	0.86 (0.63–1.17)	0.353
Initial Surgery	1.0, Ref		Ref.
Pneumonia
Neoadjuvant Therapy	0.58 (0.36, 0.94)	0.026	1.15 (0.59–2.27)	0.681
Initial Surgery	Ref.		Ref.
Pancreatic fistula
Neoadjuvant Therapy	0.66 (0.50–0.88)	<0.001	0.67 (0.49–0.92)	0.015
Initial Surgery	Ref.		Ref.
Delayed gastric emptying
Neoadjuvant Therapy	0.75 (0.61–0.93)	0.008	0.80 (0.59–1.06)	0.124
Initial Surgery	Ref.		Ref.
Perioperative transfusion
Neoadjuvant Therapy	1.42 (1.20–1.68)	<0.001	1.12 (0.88–1.43)	0.344
Initial Surgery	Ref.		Ref.

SSI surgical site infection; CI confidence interval;

^*Odds Ratio was adjusted for: age, sex, body mass index, preoperative steroid use, wound classification, operative time (hours), preoperative biliary stenting, preoperative jaundice, preoperative albumin, preoperative anemia, pancreatic duct size, gland texture, presence of pancreatic fistula, and operative reconstruction (i.e. pylorus-sparing pancreaticoduodenectomy, and pancreaticojejunal vs pancreaticogastrostomy